CDE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CDE is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The company’s fundamentals are very strong, but the stock is trading near fair value after a big run, technical momentum is mixed, and analyst views have recently become more cautious. Since the investor is impatient and does not want to wait for a better entry, I would still not call this a buy today; I would hold and wait for either a clearer technical breakout or a deeper pullback.
Current price is 18.25, slightly above the previous close of 18.12, but the broader tape shows a weak setup after a regular-session drop earlier in the day. MACD histogram is negative, though contracting, which suggests downside momentum is easing but not yet reversing. RSI_6 at 48.69 is neutral, so there is no strong oversold or breakout signal. Moving averages are converging, implying a consolidation phase rather than a confirmed uptrend. Key levels: pivot 18.358, resistance 19.512, support 17.205. The stock is sitting close to pivot, but not yet showing decisive upside strength. Based on pattern analysis, near-term probability leans slightly bearish over the next day/week/month.
Q1 2026 financials were outstanding: revenue rose 137.79% YoY to 856.2M, net income rose 639.85% YoY to 246.8M, EPS rose 483.33% YoY to 0.35, and gross margin expanded to 49.8%. Hedge funds are strongly buying, with reported buying up 65,952.68% over the last quarter. Analyst coverage earlier in the year was broadly positive, with multiple Buy/Outperform ratings and targets in the mid-20s to 40 range. Options data is bullish, and the company has strong momentum in profitability and margins. Latest quarter season: Q1 2026.
Roth also lowered its target from 29 to 24 due to lower gold and silver prices and cost guidance impact. The technical setup is not strong: MACD is negative, RSI is neutral, and trend indicators are mixed. Price action is below the more optimistic analyst targets and the stock trend model suggests downside over the near term. Insider activity is neutral, so there is no supportive insider buying signal. No recent congress trading data is available.
Latest quarter: Q1 2026. Financial performance was very strong, with revenue up sharply 137.79% YoY to 856.2M, net income up 639.85% YoY to 246.8M, EPS up 483.33% YoY to 0.35, and gross margin improving to 49.8%. This shows excellent growth and expanding profitability, which is a major positive for a long-term investor.
Analyst trend has been mixed but recently more cautious. Earlier ratings were mostly bullish: Canaccord upgraded to Buy, BMO and ATB were positive, and CIBC initiated at Outperform with a very high target. However, recent action turned softer: Cantor downgraded CDE to Hold and cut its target to 19, describing the shares as fairly valued after Q1, while Roth lowered its target to 24 from 29 though keeping Buy. Wall Street’s pro view is that the company has strong scale, improved cash flow potential, and excellent operational results. The con view is that much of the good news is already reflected in the price, especially after the recent rally.
